Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in the First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06091943 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT06091943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06091943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in the First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2023
Completion date
August 4, 2026
Enrollment
62 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer